| Type | Biotechnology |
|---|---|
| Nasdaq: BNTC | |
| Industry | RNA interference |
| Founded | 1997 |
| Headquarters | Melbourne, Victoria, Australia |
Key people | Michael Graham (Founding Scientist & Head of Discovery) |
| Products | Gene silencing, Gene expression, RNA interference (ddRNAi) |
| Website | www.benitec.com |
Benitec Biopharma Limited (ASX: BLT) is an Australian biotechnology company founded in 1997.[1] It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.[2]
The CSIRO has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research.[3]
Research and development
Benitec Biopharma is researching ddRNAi in the following fields:
- Hepatitis B (under development with partner Biomics Biotechnologies)[4])
- Oculopharyngeal muscular dystrophy (OPMD)[5][6]
References
- ↑ "Benitec Biopharma". Australian Securities Exchange. Retrieved 11 April 2012.
- ↑ "GlobalData Financial and Strategic SWOT Analysis Review". GlobalData. Archived from the original on 24 January 2013. Retrieved 11 April 2012.
- ↑ "Licensing RNAi gene technology. CSIRO. 14 Oct 2011". CSIRO. Archived from the original on 18 May 2012. Retrieved 12 April 2012.
- ↑ "Biomics Biotechnologies – Pipeline". Biomics Biotechnologies. Archived from the original on 14 December 2015. Retrieved 21 January 2014.
- ↑ "Benitec Biopharma Annual Report 2011" (PDF). Benitec. Archived from the original (PDF) on 19 July 2013. Retrieved 16 January 2014.
External links
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.